Cencora COR
Cencora is a pharmaceutical distribution company that acts as an intermediary between manufacturers and pharmacies, hospitals, and other healthcare providers, generating revenue from the volume of products it distributes. Cencora is a pharmaceutical distributor with a high-volume, razor-thin margin model (operating margin of 1.41%), but with exceptional returns on capital (ROE 96.87%, ROIC 26.89%) and earnings growth of 11.90%, which the market values at a forward P/E of 15.48, reasonable for its profile.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Cencora is a pharmaceutical distribution company that acts as an intermediary between manufacturers and pharmacies, hospitals, and other healthcare providers, generating revenue from the volume of products it distributes. Cencora is a pharmaceutical distributor with a high-volume, razor-thin margin model (operating margin of 1.41%), but with exceptional returns on capital (ROE 96.87%, ROIC 26.89%) and earnings growth of 11.90%, which the market values at a forward P/E of 15.48, reasonable for its profile.
Score by category
| Category | Score |
|---|---|
| Financial health | 4.3 |
| Quality / Moat | 6.3 |
| Valuation | 6.2 |
| Growth | 6.1 |
| Dividend | 4.3 |
| Momentum | 5.7 |
| Risk & Context | 7.9 |
OVERALL SCORE: 6.0/10
Context and risks
The US pharmaceutical distribution business is subject to regulatory pressure on drug prices and supply chain margins, a sector risk not captured by financial metrics. However, Cencora's high-volume model with very thin margins (1.41% operating) makes it sensitive to any change in pricing regulation.
News considered in the analysis
- Cencora Sees Specialty Strategy Fueling Growth Into Fiscal 2027 — La estrategia de especialidad es un motor de crecimiento conocido y ya parcialmente descontado, pero refuerza la tesis de crecimiento a medio plazo.
- Can CAH's MSO Expansion Unlock Growth in Specialty Care Delivery? — La expansión de MSO (servicios de gestión para médicos especialistas) es una oportunidad de crecimiento, pero su materialización aún no está garantizada.
- AbbVie vs. Pfizer: Which Healthcare Stock Makes Your Portfolio Healthier in 2026? — Listículo comparativo genérico sin información nueva sobre Cencora.
- AbbVie vs. Novo Nordisk: Which Drug Giant Stock Is a Better Buy in 2026? — Listículo comparativo genérico sin información nueva sobre Cencora.
- AbbVie vs. Eli Lilly: Which Star Pharma Stock Is a Better Buy in 2026? — Listículo comparativo genérico sin información nueva sobre Cencora.
Verdict: Hold: the combination of high returns on capital, stable growth, and reasonable valuation (PEG 0.64) makes it attractive, but the 1.41% operating margin and 2.10x EBITDA debt limit upside potential.
Main risk: The main risk is US regulatory pressure on drug prices, which could further compress an already razor-thin operating margin (1.41%) in a low-margin distribution business.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →